Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial

著录项

• 来源
  《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2018年第3期|共2页
• 作者

  Sattva S. Neelapu; Frederick L. Locke; Nancy L. Bartlett; Lazaros J. Lekakis; David Miklos; Eric Jacobsen; Ira Braunschweig; Olalekan Oluwole; Tanya Siddiqi; Yi Lin; John Timmerman; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; Jeff Wiezorek; William Y. Go;

  展开▼
• 作者单位

  The University of Texas MD Anderson Cancer Center;

  Moffitt Cancer Center;

  Washington University;

  Adult Stem Cell Transplant Program University of Miami Hospital and Clinics Sylvester;

  Stanford University;

  Dana-Farber Cancer Institute;

  Montefiore Medical Center Albert Einstein College of Medicine;

  Vanderbilt-Ingram Cancer Center;

  City of Hope National Medical Center;

  Division of Hematology Mayo Clinic;

  UCLA David Geffen School of Medicine;

  University of Rochester School of Medicine;

  Kite Pharma;

  Kite Pharma;

  Kite Pharma Inc.;

  Kite Pharma;

  Kite Pharma;

  Kite Pharma;

  Kite Pharma;

  Kite Pharma;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 治疗学;
• 关键词